BHVN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Biohaven Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 12 Deadline in Securities Class Action – BHVN

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities between March 24, 2023, and May 14, 2025, of the September 12, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Biohaven Ltd. for allegedly making false and misleading statements regarding the regulatory prospects of its drug troriluzole and the efficacy of BHV-7000 for bipolar disorder [4]. - Investors who purchased Biohaven securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking in the top four for settlements since 2013 [3]. Group 3: Case Specifics - The lawsuit claims that Biohaven's public statements regarding the regulatory approval and clinical prospects of its drugs were materially false and misleading, which likely had a significant negative impact on the company's business and financial condition once the truth was revealed [4].